EphA2 Gene Targeting using Neutral Liposomal Small Interfering RNA Delivery

Solid Tumors
Aung Naing, MD
MD Anderson Cancer Center


While traditional chemotherapy has had some success in the treatment of solid tumors, a large number of patients either do not respond or relapse. Most patients with relapse or advanced cancer ultimately succumb to their disease despite aggressive treatment. Thus, there is an urgent need for successful treatments for patients with advanced/recurrent disease. EphA2 is a protein that is generally absent in most normal adult tissue; however, it has been found to be abundant in many cancers including lung, breast, prostate, colorectal, melanoma, esophageal, ovarian, uterine, and pancreatic. It is associated with a poor prognosis and is thought to play a critical role in cancer cell proliferation, survival, migration, and generation of blood supply to tumors. This phase I study will assess the safety of short interfering (si) RNAs targeting EphA2, siRNA-EphA2, in patients with advanced solid tumors. This drug targets the production of the EphA2 protein at the molecular level.

Trial Registration: ClinicalTrials.gov Identifier: NCT01591356